Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Innosuisse
Deal Size : $3.3 million
Deal Type : Funding
Details : The first project will advance lead HTX-001, an antisense oligonucleotide targeting lncRNA Wisper, a cardiac tissue-enriched driver of fibrosis in the heart and second project will aim to develop a next-g...
Product Name : HTX-001
Product Type : Large molecule
Upfront Cash : Undisclosed
May 03, 2022
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Innosuisse
Deal Size : $3.3 million
Deal Type : Funding
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Broadview Ventures
Deal Size : $20.0 million
Deal Type : Financing
Details : HAYA will use the funds from the financing to advance the discovery and development of innovative organ and cell-selective therapeutics HTX-001, that target lncRNAs to treat and potentially reverse fibros...
Product Name : HTX-001
Product Type : Large molecule
Upfront Cash : Undisclosed
May 20, 2021
Lead Product(s) : HTX-001
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Broadview Ventures
Deal Size : $20.0 million
Deal Type : Financing
LOOKING FOR A SUPPLIER?